Anxiety disorders affect 40 million Americans, making them the most common mental health condition in the country. Treatments have improved over decades, but they remain blunt instruments — SSRIs that alter serotonin across the entire brain, benzodiazepines that broadly suppress neural activity, therapy that works over months of sessions. A new discovery published in June 2026 by researchers at Spain's Institute for Neurosciences offers a glimpse at a more precise future: a specific, tiny circuit of neurons in the amygdala that can both cause anxiety and eliminate it — depending entirely on whether the circuit is in balance.
The research, led by Juan Lerma and his team at the Synaptic Physiology laboratory of the Institute for Neurosciences (a joint center of the Spanish National Research Council and Miguel Hernández University), was published this week in ScienceDaily and represents an evolution of the team's earlier iScience study. The team used genetically modified mice engineered to overexpress the Grik4 gene — which is linked to human neuropsychiatric conditions including treatment response to antidepressants — specifically in a small cluster of neurons in the basolateral amygdala.
The result was a dramatic, reproducible anxiety phenotype: the mice showed persistent anxiety-like behaviors and social withdrawal similar to symptoms seen in human conditions including generalized anxiety disorder and autism spectrum disorder.
The Circuit — and the Switch
The basolateral amygdala is a region of the brain long known to regulate fear and emotional responses. Within it, the team identified what they call "regular firing neurons" in the centrolateral amygdala — a previously undercharacterized population that, when their communication with inhibitory interneurons is disrupted by excess Grik4/GluK4 activity, generates the pathological excitability that produces anxiety and social deficits.
The key finding is that this disruption is reversible. When the researchers normalized Grik4 expression specifically in the affected neurons — restoring balance between excitatory and inhibitory communication in the circuit — the anxiety behaviors were eliminated. Not reduced. Eliminated.
"We already knew the amygdala was involved in anxiety and fear, but now we've identified a specific population of neurons whose imbalanced activity alone is sufficient to trigger pathological behaviors," said Dr. Lerma. "By identifying and correcting that imbalance, we were able to fully reverse the anxiety phenotype."
What This Could Mean for Human Treatment
The discovery's translational significance is substantial, though human applications remain years away. The Grik4 gene is associated in human genetics studies with psychiatric conditions and antidepressant response — meaning the same circuit pathway identified in this mouse model may play a role in human anxiety disorders. The fact that a single, anatomically defined circuit can both cause and reverse anxiety behaviors in mice opens the door to circuit-level interventions that do not require systemic drug exposure: approaches such as targeted deep brain stimulation, focused ultrasound neuromodulation, or precision optogenetics-derived therapeutics.
For the 40 million Americans with anxiety disorders — of whom more than half receive inadequate treatment or no treatment at all — the prospect of therapies that precisely correct the underlying neural imbalance rather than broadly altering brain chemistry represents a fundamentally different treatment model. Clinical translation is likely a decade or more away, but the discovery establishes the biological target with a clarity that prior anxiety research has lacked.
Frequently Asked Questions
Q: What brain area was targeted in this study?
A: The basolateral and centrolateral amygdala — a brain region central to emotional regulation. Researchers identified a specific population of "regular firing neurons" in the centrolateral amygdala as the key circuit element.
Q: Did this study reverse anxiety in humans?
A: No. The study was conducted in genetically modified mice. Results in animal models don't always translate to humans, but the genetic and anatomical relevance to human anxiety disorders makes this a significant finding for future research.
Q: What gene is involved?
A: Grik4, which encodes the GluK4-type glutamate receptor. Elevated Grik4/GluK4 activity in the targeted neurons increased neuronal excitability and produced anxiety and social withdrawal. Normalizing it reversed those effects.
Q: How far are we from a clinical treatment based on this discovery?
A: Likely a decade or more. The finding establishes a specific circuit target. Human applications would require development of a precise delivery method, clinical safety testing, and trials. It opens doors rather than delivering an immediate therapy.
